Collegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes Offering - Seite 3

Forward-Looking Statements

This press release includes forward-looking statements, including statements regarding the Nucynta Transaction, the financing for the Nucynta Transaction, the completion of the offering and the expected amount and intended use of the net proceeds.  Collegium may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements represent Collegium’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements.  Among those risks and uncertainties are risks related to the Nucynta Transaction, market conditions, the satisfaction of the closing conditions related to the offering and risks relating to Collegium’s business, including those described under the heading “Risk Factors” in Collegium’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and other filings with the SEC, and in the preliminary prospectus supplement related to the offering filed with the SEC on February 10, 2020.  Collegium may not consummate the offering described in this press release and, if the offering is consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above.  Any forward-looking statements included in this press release speak only as of the date of this press release. Collegium does not undertake any obligation to update the statements included in this press release for subsequent developments, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact Information

Alex Dasalla
[e-mail]